Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b

Kuo Chih Tseng, Li Hsuan Chen, Chi Yi Chen, Ting-Tsung Chang, An Liang Chou, I-Chin Wu, Pin-Nan Cheng

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Aim: Anemia during combination therapy with pegylated interferon alfa-2b plus ribavirin (RBV) for chronic hepatitis C virus (HCV) patients usually leads to RBV dose reduction or discontinuation. This study evaluated the effect of erythropoietin-beta (EPO-β) to maintain RBV dose and hemoglobin (Hb) level in chronic HCV patients treated with antiviral combination therapy. Methods: Eighty-eight chronic HCV patients who developed anemia during therapy were enrolled into this retrospective study: 55 in the EPO-β group and 33 in the untreated group. The study endpoints were to assess the RBV maintenance and the changes in Hb. Results: A higher percentage of patients with RBV maintenance was observed in the EPO-β group compared with the untreated group (nadir Hb level <10.5 g/dL; 70% vs. 38%, P = 0.020; nadir Hb < 10 g/dL; 62% vs. 27%, P = 0.046). The mean Hb change from week 12 to week 20 was higher in the EPO-β group when compared with the untreated group, especially for patients receiving a total EPO-β dose of more than 16000U (+0.70 g/dL vs. -0.32 g/dL, P = 0.023) and of 10000U-14000U (+0.60 g/dL vs. -0.32 g/dL, P = 0.023). Conclusions: Low-dose EPO-β can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.

Original languageEnglish
Pages (from-to)539-545
Number of pages7
JournalHepatology Research
Volume39
Issue number6
DOIs
Publication statusPublished - 2009 Jun 10

Fingerprint

Ribavirin
Chronic Hepatitis C
Erythropoietin
Anemia
Hemoglobins
Hepacivirus
Therapeutics
Maintenance
Antiviral Agents
peginterferon alfa-2b
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

@article{7356bf96c6bd4ea793aa1c1aec065a01,
title = "Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b",
abstract = "Aim: Anemia during combination therapy with pegylated interferon alfa-2b plus ribavirin (RBV) for chronic hepatitis C virus (HCV) patients usually leads to RBV dose reduction or discontinuation. This study evaluated the effect of erythropoietin-beta (EPO-β) to maintain RBV dose and hemoglobin (Hb) level in chronic HCV patients treated with antiviral combination therapy. Methods: Eighty-eight chronic HCV patients who developed anemia during therapy were enrolled into this retrospective study: 55 in the EPO-β group and 33 in the untreated group. The study endpoints were to assess the RBV maintenance and the changes in Hb. Results: A higher percentage of patients with RBV maintenance was observed in the EPO-β group compared with the untreated group (nadir Hb level <10.5 g/dL; 70{\%} vs. 38{\%}, P = 0.020; nadir Hb < 10 g/dL; 62{\%} vs. 27{\%}, P = 0.046). The mean Hb change from week 12 to week 20 was higher in the EPO-β group when compared with the untreated group, especially for patients receiving a total EPO-β dose of more than 16000U (+0.70 g/dL vs. -0.32 g/dL, P = 0.023) and of 10000U-14000U (+0.60 g/dL vs. -0.32 g/dL, P = 0.023). Conclusions: Low-dose EPO-β can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.",
author = "Tseng, {Kuo Chih} and Chen, {Li Hsuan} and Chen, {Chi Yi} and Ting-Tsung Chang and Chou, {An Liang} and I-Chin Wu and Pin-Nan Cheng",
year = "2009",
month = "6",
day = "10",
doi = "10.1111/j.1872-034X.2009.00489.x",
language = "English",
volume = "39",
pages = "539--545",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b

AU - Tseng, Kuo Chih

AU - Chen, Li Hsuan

AU - Chen, Chi Yi

AU - Chang, Ting-Tsung

AU - Chou, An Liang

AU - Wu, I-Chin

AU - Cheng, Pin-Nan

PY - 2009/6/10

Y1 - 2009/6/10

N2 - Aim: Anemia during combination therapy with pegylated interferon alfa-2b plus ribavirin (RBV) for chronic hepatitis C virus (HCV) patients usually leads to RBV dose reduction or discontinuation. This study evaluated the effect of erythropoietin-beta (EPO-β) to maintain RBV dose and hemoglobin (Hb) level in chronic HCV patients treated with antiviral combination therapy. Methods: Eighty-eight chronic HCV patients who developed anemia during therapy were enrolled into this retrospective study: 55 in the EPO-β group and 33 in the untreated group. The study endpoints were to assess the RBV maintenance and the changes in Hb. Results: A higher percentage of patients with RBV maintenance was observed in the EPO-β group compared with the untreated group (nadir Hb level <10.5 g/dL; 70% vs. 38%, P = 0.020; nadir Hb < 10 g/dL; 62% vs. 27%, P = 0.046). The mean Hb change from week 12 to week 20 was higher in the EPO-β group when compared with the untreated group, especially for patients receiving a total EPO-β dose of more than 16000U (+0.70 g/dL vs. -0.32 g/dL, P = 0.023) and of 10000U-14000U (+0.60 g/dL vs. -0.32 g/dL, P = 0.023). Conclusions: Low-dose EPO-β can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.

AB - Aim: Anemia during combination therapy with pegylated interferon alfa-2b plus ribavirin (RBV) for chronic hepatitis C virus (HCV) patients usually leads to RBV dose reduction or discontinuation. This study evaluated the effect of erythropoietin-beta (EPO-β) to maintain RBV dose and hemoglobin (Hb) level in chronic HCV patients treated with antiviral combination therapy. Methods: Eighty-eight chronic HCV patients who developed anemia during therapy were enrolled into this retrospective study: 55 in the EPO-β group and 33 in the untreated group. The study endpoints were to assess the RBV maintenance and the changes in Hb. Results: A higher percentage of patients with RBV maintenance was observed in the EPO-β group compared with the untreated group (nadir Hb level <10.5 g/dL; 70% vs. 38%, P = 0.020; nadir Hb < 10 g/dL; 62% vs. 27%, P = 0.046). The mean Hb change from week 12 to week 20 was higher in the EPO-β group when compared with the untreated group, especially for patients receiving a total EPO-β dose of more than 16000U (+0.70 g/dL vs. -0.32 g/dL, P = 0.023) and of 10000U-14000U (+0.60 g/dL vs. -0.32 g/dL, P = 0.023). Conclusions: Low-dose EPO-β can maintain RBV dose and increase Hb levels in anemic chronic HCV patients receiving combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=66449084721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449084721&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2009.00489.x

DO - 10.1111/j.1872-034X.2009.00489.x

M3 - Article

VL - 39

SP - 539

EP - 545

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 6

ER -